{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:20:40Z","timestamp":1792171240986,"version":"4.4.0"},"reference-count":47,"publisher":"American Society of Hematology","issue":"1","license":[{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,4]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The translocation t(11;14) occurs in 20% of patients with multiple myeloma (MM) and results in the upregulation of CCND1. Nearly two-thirds of t(11;14) MM cells are BCL2 primed and highly responsive to the oral BCL2 inhibitor venetoclax. Although it is evident that this unique sensitivity to venetoclax depends on the Bcl-2 homology domain 3\u2013 proapoptotic protein priming of BCL2, the biology underlying t(11;14) MM dependency on BCL2 is poorly defined. Importantly, the epigenetic regulation of t(11;14) transcriptomes and its impact on gene regulation and clinical response to venetoclax remain elusive. In this study, by integrating assay for transposase-accessible chromatin by sequencing (ATAC-seq) and RNA-seq at the single-cell level in primary MM samples, we have defined the epigenetic regulome and transcriptome associated with t(11;14) MM. A B-cell\u2013like epigenetic signature was enriched in t(11;14) MM, confirming its phylogeny link to B-cell rather than plasma cell biology. Of note, a loss of a B-cell\u2013like epigenetic signature with a gain of canonical plasma cell transcription factors was observed at the time of resistance to venetoclax. In addition, MCL1 and BCL2L1 copy number gains and structural rearrangements were linked to venetoclax resistance in patients with t(11;14) MM. To date, this is the first study in which both single-cell (sc) ATAC-seq and scRNA-seq analysis are integrated into primary MM cells to obtain a deeper resolution of the epigenetic regulome and transcriptome associated with t(11;14) MM biology and venetoclax resistance.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023020276","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T20:14:31Z","timestamp":1695240871000},"page":"42-56","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":34,"title":["Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4202-7127","authenticated-orcid":false,"given":"No\u00e9mie","family":"Leblay","sequence":"first","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7688-6843","authenticated-orcid":false,"given":"Sungwoo","family":"Ahn","sequence":"additional","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada"},{"name":"2Department of Chemical and Petroleum Engineering, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1739-2162","authenticated-orcid":false,"given":"R\u00e9mi","family":"Tilmont","sequence":"additional","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansour","family":"Poorebrahim","sequence":"additional","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjan","family":"Maity","sequence":"additional","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Lee","sequence":"additional","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Barakat","sequence":"additional","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4218-7294","authenticated-orcid":false,"given":"Jean-Baptiste","family":"Alberge","sequence":"additional","affiliation":[{"name":"3Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0770-3150","authenticated-orcid":false,"given":"Sarthak","family":"Sinha","sequence":"additional","affiliation":[{"name":"4Department of Comparative Biology and Experimental Medicine, Faculty of Veterinary Medicine, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9197-9060","authenticated-orcid":false,"given":"Arzina","family":"Jaffer","sequence":"additional","affiliation":[{"name":"4Department of Comparative Biology and Experimental Medicine, Faculty of Veterinary Medicine, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9810-3566","authenticated-orcid":false,"given":"Benjamin G.","family":"Barwick","sequence":"additional","affiliation":[{"name":"5Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA"},{"name":"6Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9436-8815","authenticated-orcid":false,"given":"Lawrence H.","family":"Boise","sequence":"additional","affiliation":[{"name":"5Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA"},{"name":"6Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-7034","authenticated-orcid":false,"given":"Nizar","family":"Bahlis","sequence":"additional","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2595-3647","authenticated-orcid":false,"given":"Paola","family":"Neri","sequence":"additional","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2024010416273125500_bib1","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3390\/cells10020336","article-title":"Genetic abnormalities in multiple myeloma: prognostic and therapeutic implications","volume":"10","author":"Cardona-Benavides","year":"2021","journal-title":"Cells"},{"issue":"7","key":"2024010416273125500_bib2","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.3390\/cancers13071686","article-title":"Emerging therapeutic strategies to overcome drug resistance in multiple myeloma","volume":"13","author":"Davis","year":"2021","journal-title":"Cancers"},{"issue":"26","key":"2024010416273125500_bib3","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1200\/JCO.2005.05.021","article-title":"Molecular pathogenesis and a consequent classification of multiple myeloma","volume":"23","author":"Bergsagel","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024010416273125500_bib4","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2010-04-279539","article-title":"Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma","volume":"117","author":"Walker","year":"2011","journal-title":"Blood"},{"key":"2024010416273125500_bib5","doi-asserted-by":"crossref","first-page":"100643","DOI":"10.1016\/j.blre.2019.100643","article-title":"The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma","volume":"41","author":"Paner","year":"2020","journal-title":"Blood Rev"},{"issue":"10","key":"2024010416273125500_bib6","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/sj.leu.2403091","article-title":"t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma","volume":"17","author":"Garand","year":"2003","journal-title":"Leukemia"},{"issue":"3","key":"2024010416273125500_bib7","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2002-11-3333","article-title":"CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma","volume":"102","author":"Robillard","year":"2003","journal-title":"Blood"},{"issue":"3","key":"2024010416273125500_bib8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"2024010416273125500_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The BCL-2 protein family: opposing activities that mediate cell death","volume":"9","author":"Youle","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"2024010416273125500_bib10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"8","key":"2024010416273125500_bib11","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024010416273125500_bib12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024010416273125500_bib13","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1111\/bjh.16483","article-title":"Carfilzomib, venetoclax and dexamethasone for relapsed\/refractory multiple myeloma","volume":"189","author":"Boccon-Gibod","year":"2020","journal-title":"Br J Haematol"},{"issue":"22","key":"2024010416273125500_bib14","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2024010416273125500_bib15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/leu.2013.216","article-title":"The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma","volume":"28","author":"Touzeau","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"2024010416273125500_bib16","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.3324\/haematol.2016.160408","article-title":"Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14)","volume":"102","author":"Touzeau","year":"2017","journal-title":"Haematologica"},{"issue":"32","key":"2024010416273125500_bib17","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1200\/JCO.21.00443","article-title":"Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14)","volume":"39","author":"Bahlis","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024010416273125500_bib18","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"26","key":"2024010416273125500_bib19","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1182\/blood.2020007899","article-title":"Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression","volume":"137","author":"Gupta","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2024010416273125500_bib20","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/leu.2015.350","article-title":"Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax","volume":"30","author":"Matulis","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"2024010416273125500_bib21","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.bbrc.2011.08.118","article-title":"Noxa controls Mule-dependent Mcl-1 ubiquitination through the regulation of the Mcl-1\/USP9X interaction","volume":"413","author":"Gomez-Bougie","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"issue":"19","key":"2024010416273125500_bib22","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood-2017-09-808063","article-title":"Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma","volume":"131","author":"Jin","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2024010416273125500_bib23","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.cell.2014.08.009","article-title":"Determination and inference of eukaryotic transcription factor sequence specificity","volume":"158","author":"Weirauch","year":"2014","journal-title":"Cell"},{"issue":"5","key":"2024010416273125500_bib24","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1182\/blood-2008-01-136440","article-title":"Spi-B inhibits human plasma cell differentiation by repressing BLIMP1 and XBP-1 expression","volume":"112","author":"Schmidlin","year":"2008","journal-title":"Blood"},{"key":"2024010416273125500_bib25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fgene.2013.00109","article-title":"The role of endoplasmic reticulum stress in maintaining and targeting multiple myeloma: a double-edged sword of adaptation and apoptosis","volume":"4","author":"White-Gilbertson","year":"2013","journal-title":"Front Genet"},{"issue":"10","key":"2024010416273125500_bib26","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1084\/jem.20090738","article-title":"XBP1 governs late events in plasma cell differentiation and is not required for antigen-specific memory B cell development","volume":"206","author":"Todd","year":"2009","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"2024010416273125500_bib27","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1172\/JCI200521848","article-title":"The unfolded protein response sensor IRE1\u03b1 is required at 2 distinct steps in B cell lymphopoiesis","volume":"115","author":"Zhang","year":"2005","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"2024010416273125500_bib28","doi-asserted-by":"crossref","first-page":"e13052","DOI":"10.1371\/journal.pone.0013052","article-title":"IRE1\u03b1 disruption causes histological abnormality of exocrine tissues, increase of blood glucose level, and decrease of serum immunoglobulin level","volume":"5","author":"Iwawaki","year":"2010","journal-title":"PLoS One"},{"issue":"2","key":"2024010416273125500_bib29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrc3877","article-title":"The RUNX family: developmental regulators in cancer","volume":"15","author":"Ito","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"20","key":"2024010416273125500_bib30","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2022016040","article-title":"Single-cell multiomics reveal the scale of multi-layered adaptations enabling CLL relapse during venetoclax therapy","volume":"140","author":"Thijssen","year":"2022","journal-title":"Blood"},{"issue":"5741","key":"2024010416273125500_bib31","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1126\/science.1114297","article-title":"PUMA couples the nuclear and cytoplasmic pro-apoptotic function of p53","volume":"309","author":"Chipuk","year":"2005","journal-title":"Science"},{"issue":"suppl 1","key":"2024010416273125500_bib32","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2019-127593","article-title":"Mutations and copy number gains of the BCL2 family members mediate resistance to venetoclax in multiple myeloma (MM) patients [abstract]","volume":"134","author":"Neri","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2024010416273125500_bib33","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2019-131981","article-title":"IGLL5-BCL2L1 rearrangement with loss of BCL2 dependency as mechanism of venetoclax resistance in multiple myeloma (MM) [abstract]","volume":"134","author":"Alberge","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2024010416273125500_bib34","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ajh.26083","article-title":"Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed\/refractory t(11;14) multiple myeloma","volume":"96","author":"Kaufman","year":"2021","journal-title":"Am J Hematol"},{"issue":"11","key":"2024010416273125500_bib35","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1158\/0008-5472.CAN-06-4322","article-title":"Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma","volume":"67","author":"Gomez-Bougie","year":"2007","journal-title":"Cancer Res"},{"issue":"8","key":"2024010416273125500_bib36","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1038\/s41375-019-0403-2","article-title":"RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation","volume":"33","author":"Zhou","year":"2019","journal-title":"Leukemia"},{"issue":"14","key":"2024010416273125500_bib37","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.3390\/cancers14143456","article-title":"Targeting acute myeloid leukemia with venetoclax; biomarkers for sensitivity and rationale for venetoclax-based combination therapies","volume":"14","author":"Griffioen","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"2024010416273125500_bib38","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.2018893982","article-title":"RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1","volume":"134","author":"Mill","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2024010416273125500_bib39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41420-022-01009-1","article-title":"The BCL-2 inhibitor ABT-199\/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA","volume":"8","author":"Weller","year":"2022","journal-title":"Cell Death Discov"},{"issue":"10","key":"2024010416273125500_bib40","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.15252\/embr.201642195","article-title":"The integrated stress response","volume":"17","author":"Pakos-Zebrucka","year":"2016","journal-title":"EMBO Rep"},{"issue":"10","key":"2024010416273125500_bib41","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1038\/bjc.2012.139","article-title":"The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction","volume":"106","author":"Descamps","year":"2012","journal-title":"Br J Cancer"},{"issue":"1","key":"2024010416273125500_bib42","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/s41467-020-15051-z","article-title":"Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma","volume":"11","author":"Bajpai","year":"2020","journal-title":"Nat Commun"},{"issue":"4","key":"2024010416273125500_bib43","first-page":"127","article-title":"NOXA the BCL-2 family member behind the scenes in cancer treatment","volume":"1","author":"Dumont","year":"2020","journal-title":"J\u00a0Cell Signal"},{"issue":"12","key":"2024010416273125500_bib44","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"2024010416273125500_bib45","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1101\/gad.1304105","article-title":"pro-apoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins","volume":"19","author":"Willis","year":"2005","journal-title":"Genes Dev"},{"issue":"22","key":"2024010416273125500_bib46","doi-asserted-by":"crossref","first-page":"16223","DOI":"10.1074\/jbc.M611186200","article-title":"Functional linkage between NOXA and Bim in mitochondrial apoptotic events","volume":"282","author":"Han","year":"2007","journal-title":"J\u00a0Biol Chem"},{"issue":"5","key":"2024010416273125500_bib47","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.molcel.2010.11.035","article-title":"The pro-apoptotic function of Noxa in human leukemia cells is regulated by the kinase Cdk5 and by glucose","volume":"40","author":"Lowman","year":"2010","journal-title":"Mol Cell"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/1\/42\/2180127\/blood_bld-2023-020276-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/1\/42\/2180127\/blood_bld-2023-020276-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T16:28:12Z","timestamp":1704385692000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/1\/42\/497954\/Integrated-epigenetic-and-transcriptional-single"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,4]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023020276","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]}}}